Candel Therapeutics, Inc. Stock Price, News & Analysis

Candel Therapeutics (Nasdaq: CADL) announces the appointment of Jason A. Amello as Chief Financial Officer and Garrett Nichols, MD, MS as Chief Medical Officer, effective September 21, 2022. Mr. Amello replaces John Canepa, who is moving on for personal reasons. Both new leaders bring extensive experience in biopharmaceuticals, with Amello's previous roles including CFO at Saniona AB and Akebia Therapeutics, and Nichols having served as CMO at Istari Oncology. Their leadership is expected to enhance Candel's efforts in developing oncolytic viral immunotherapies for cancer treatment.

Candel Therapeutics, Inc. (Nasdaq: CADL) announced participation in two investor conferences. CEO Paul Peter Tak will attend Citi's 17th Annual BioPharma Conference in Boston on September 7. Candel will also present at the H.C. Wainwright 24th Annual Global Investment Conference via webcast on September 12 at 7:00 AM ET. The company focuses on oncolytic viral immunotherapies for cancer treatment, with lead products CAN-2409 and CAN-3110. A webcast of the latter presentation will be archived for up to 90 days. Visit Candel's website for more details.

Candel Therapeutics, Inc. (Nasdaq: CADL) reported its Q2 2022 financial results, revealing a net loss of $4.1 million, a significant decrease from $17.1 million in Q2 2021. The company maintains a strong cash position of $86.8 million, sufficient to fund operations into Q1 2024. Candel announced a promising 87.5% disease control rate from its phase 2 clinical trial of CAN-2409 in NSCLC at ASCO 2022. Upcoming milestones include phase 3 trials for high-grade glioma and updates on their enLIGHTEN™ Discovery Platform.

Candel Therapeutics, Inc. (Nasdaq: CADL) announced the appointment of three new board members, Gary Nabel, Joseph C. Papa, and Renee Gaeta, effective August 8, 2022. Their extensive experience in biopharmaceuticals and finance is expected to bolster Candel's strategies in oncolytic viral immunotherapies for cancer treatment. The new directors replace outgoing members, maintaining the board's nine-member structure. Candel aims to leverage this leadership change to enhance its growth and innovation in the cancer treatment space.

Candel Therapeutics reported promising findings from its Phase 2 clinical trial of CAN-2409 in patients with advanced non-small cell lung cancer (NSCLC) at the ASCO Annual Meeting.

The trial demonstrated a 87.5% disease control rate in patients previously progressing on anti-PD-1 therapy, with 62.5% showing durable stabilization. A 15% partial response rate was observed, along with tumor regression in both injected and uninjected lesions. The treatment was well tolerated, highlighting CAN-2409's potential as a viable option for NSCLC patients lacking effective alternatives.

Candel Therapeutics, a late clinical-stage biopharmaceutical company focused on oncolytic viral immunotherapies, announced that CEO Paul Peter Tak will present at H.C. Wainwright’s Annual Global Investment Conference.

Date: May 24, 2022, Time: 7:00 am ET for on-demand viewing. Candel's leading candidates include CAN-2409 and CAN-3110, designed to induce immune responses against cancer. For more details, visit Candel Therapeutics’ website.

Candel Therapeutics (Nasdaq: CADL) reported its Q1 2022 financial results and outlined key advancements in oncolytic viral immunotherapy for cancer. The company strengthened its cash position with a $20 million debt financing and reported cash equivalents of $94.3 million as of March 31, 2022. Research and development expenses rose to $5.4 million, reflecting increased clinical trial activities. Notably, the net loss decreased to $874,000 compared to $4.5 million in Q1 2021. Candel is set to present pivotal clinical data at the upcoming ASCO Annual Meeting in June 2022.

Candel Therapeutics, Inc. (Nasdaq: CADL) announced the acceptance of an abstract for presentation at the ASCO Annual Meeting 2022, scheduled for June 3-7 at McCormick Place, Chicago. The abstract will present data from a phase 2 clinical trial on CAN-2409 and valacyclovir in combination with anti-PD-1/PD-L1 agents for treating stage III/IV NSCLC patients. Key details include:

• Abstract Title: First report of safety/tolerability and preliminary antitumor activity of CAN-2409
• Presenter: Charu Aggarwal
• Date: June 6, 2022
• Abstract Number: 9037

Candel Therapeutics (CADL) reported a strong cash position of $82.6 million as of December 31, 2021, up from $35.1 million in 2020, bolstered by a successful IPO. Despite a net loss of $36.1 million for the year, the company plans to present key clinical trial data in 2022, seeking to advance its oncolytic viral immunotherapies for various cancers. Operating expenses increased to $25.9 million, driven by R&D and administrative costs linked to its growth strategy. Candel is positioned for critical milestones with upcoming data readouts expected in mid-2022.